Precigen Q4 2023 Earnings Report
Key Takeaways
Precigen reported its full year 2023 financial results, with key highlights including progress in its AdenoVerse and UltraCAR-T programs. The company anticipates a transformative year in 2024, with pivotal Phase 2 data expected in Q2 and a BLA submission for PRGN-2012 in the second half of the year. A $10.4 million impairment charge was recorded in Q4 related to Exemplar subsidiary.
Anticipates presenting pivotal Phase 2 data in the second quarter and submitting a BLA for PRGN-2012 in the second half of 2024.
Preparing manufacturing facility and commercial operations in anticipation of the launch of PRGN-2012 in 2025.
Exciting updates expected from UltraCAR-T programs, which have garnered significant interest from potential partners.
Evaluating various financing opportunities to strengthen the balance sheet in preparation for the potential commercial launch of PRGN-2012 in 2025.